Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. (NYSE: AVNS) is a leading medical technology company based in Alpharetta, Georgia. Specializing in breakthrough solutions, Avanos focuses on helping patients recover from surgery and move back to their normal lives while minimizing opioid use.
The company offers innovative medical devices and services in over 90 countries, addressing critical healthcare needs. Avanos' key areas of operation include Digestive Health and Pain Management and Recovery. Recently, they've integrated their Chronic Care and Pain Management franchises into a single commercial entity. This restructuring has enabled Avanos to enhance its focus on digestive health and non-opioid pain relief solutions.
Avanos made headlines with its acquisition of Diros Technology Inc., a leader in radiofrequency (RF) ablation technology for chronic pain management. Diros' RF Trident™ technology, known for delivering precise, minimally invasive pain treatment, complements Avanos' COOLIEF* Cooled Radiofrequency offerings. This acquisition is expected to broaden Avanos' market reach and enhance its portfolio of non-opioid pain management products.
In 2023, Avanos reported steady financial growth, with notable performance in its Digestive Health sector. Despite a slight overall sales decline, the company's operational focus and strategic acquisitions have positioned it well for future growth. Avanos continues its three-year transformation initiative, emphasizing optimized commercial operations, product portfolio transformation, cost management, and strategic M&A activity.
Moreover, Avanos recently aligned with the UK's National Institute for Health and Care Excellence (NICE) guidelines, supporting the use of RF ablation for osteoarthritic knee pain—an endorsement that could spur similar guidelines globally.
However, Avanos faced challenges, including a voluntary recall of certain gastric-jejunal feeding tube kits due to sterility concerns related to pre-filled syringes. Despite these hurdles, the company remains resolute in its commitment to delivering superior healthcare solutions.
For more information, visit www.avanos.com and follow Avanos Medical on Twitter, LinkedIn, and Facebook.
Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on August 3, 2021, at 9 a.m. ET, to discuss its second-quarter 2021 financial results and business highlights. A news release detailing these results will precede the call. Hosted by CEO Joe Woody and CFO Michael Greiner, interested parties can join by calling 877-240-5772 in the U.S. A replay will be available the same day at noon ET. Avanos Medical focuses on innovative healthcare solutions, operating in over 90 countries.
Avanos Medical, Inc. (NYSE: AVNS) has appointed Moji James as senior vice president & general counsel, effective immediately. With over 25 years of legal experience, James has previously served as chief legal officer at Tmunity Therapeutics and general counsel at Iroko Pharmaceuticals. Her extensive background in healthcare law and compliance is expected to enhance Avanos' strategic direction. CEO Joe Woody praised her qualifications, emphasizing the importance of her role in advancing the company's vision and addressing key healthcare needs.
Avanos Medical (NYSE: AVNS) announced an upcoming presentation by CEO Joe Woody at the Virtual 2021 Raymond James Human Health Innovation Conference on June 22 at 10:40 a.m. ET. A live webcast will be accessible in the Investors section of their website, with an archived version also available. Avanos is dedicated to providing innovative medical device solutions to enhance patient care and reduce opioid dependency.
Avanos Medical reported Q1 2021 results, with net sales of $181 million, unchanged year-over-year. The company experienced a net loss of $8 million, contrasting with a net income of $4 million last year. Adjusted net income rose to $11 million from $8 million. Gross margin decreased to 51% from 57%, primarily due to increased freight costs. The company expects 2021 net sales to increase by 2 to 4% and projects adjusted diluted earnings per share between $1.10 and $1.25. Free cash flow was an outflow of $9 million.
Avanos Medical will host a conference call on May 7, 2021, at 9 a.m. ET, to discuss its financial results for the first quarter of 2021. A news release detailing these results will be issued before market opening that day. The call will be led by CEO Joe Woody and CFO Michael Greiner. Investors can join by dialing 877-240-5772 in the U.S. A replay will be available starting at noon ET on the same day. Avanos Medical focuses on innovative medical solutions, aiming to reduce opioid use and enhance patient recovery.
Avanos Medical, Inc. (NYSE: AVNS) will have CEO Joe Woody present at the Virtual KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at approximately 2 p.m. ET. A live webcast of the presentation can be accessed in the Investors section of Avanos Medical's website, where it will also be archived. Avanos Medical is dedicated to enhancing patient care and reducing opioid use through innovative medical devices.
Avanos Medical (NYSE: AVNS) announced that Michael Greiner, senior vice president and chief financial officer, will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 1 at approximately 3:50 p.m., ET. A live webcast of the presentation will be available on Avanos' Investors section and archived on their website.
Avanos Medical reported Q4 2020 net sales of $185 million, down 3% year-over-year, while full-year sales rose 3% to $715 million. The Q4 net loss was $47 million, compared to a loss of $6 million last year. Adjusted net income for the quarter was $13 million, down from $16 million a year ago. The company implemented a restructuring program projected to yield $7 million in annual savings. Notably, the restructuring led to an overall charge of $25-$30 million. Despite pandemic challenges, the company aims for growth and margin improvement in 2021.
Avanos Medical (NYSE: AVNS) will hold a conference call on Feb. 18, 2021, at 9 a.m. ET, to discuss its fourth quarter and full-year 2020 financial results. A news release detailing these results will be issued before market open that day. The call will be hosted by CEO Joe Woody and CFO Michael Greiner. Investors can join the call by dialing 877-240-5772 or access a live webcast via the Avanos Medical website. A replay will be available starting Feb. 18 at noon ET for one week.
Avanos Medical (NYSE: AVNS) will have CEO Joe Woody present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at approximately 2 p.m. ET. This presentation will be available via a live webcast, including a Q&A session, accessible through the Investors section of Avanos Medical's website and will be archived for later viewing. The company focuses on innovative healthcare solutions aimed at reducing opioid use and improving patient recovery.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
What does Avanos Medical specialize in?
Where is Avanos Medical headquartered?
What was a significant recent acquisition by Avanos Medical?
What are Avanos Medical's primary product categories?
How is Avanos Medical contributing to non-opioid pain management?
What recent endorsement did Avanos receive from NICE?
What is the focus of Avanos Medical's three-year transformation initiative?
How does Avanos Medical market its products?
What was one of the recent challenges faced by Avanos Medical?
Where can I find more information about Avanos Medical?
